603087 甘李药业
已收盘 09-14 15:00:00
资讯
新帖
简况
每周股票复盘：甘李药业（603087）GZC8072片完成首例受试者给药
证券之星 · 09-13 01:48
每周股票复盘：甘李药业（603087）GZC8072片完成首例受试者给药
甘李药业Gzc8072首个人体I期临床研究完成首例受试者给药
美股速递 · 09-09
甘李药业Gzc8072首个人体I期临床研究完成首例受试者给药
甘李药业（603087）披露GZC8072片Ⅰ期临床试验完成首例受试者给药公告，9月8日股价上涨0.39%
证券之星 · 09-08
甘李药业（603087）披露GZC8072片Ⅰ期临床试验完成首例受试者给药公告，9月8日股价上涨0.39%
甘李药业(603087.SH)：GZC8072片Ⅰ期临床试验完成首例受试者给药
智通财经 · 09-07
甘李药业(603087.SH)：GZC8072片Ⅰ期临床试验完成首例受试者给药
甘李药业：9月3日董事李智、宋维强减持股份合计1.3万股
证券之星 · 09-04
甘李药业：9月3日董事李智、宋维强减持股份合计1.3万股
甘李药业：高管减持潮背后，财务与转型双重考验显现
新浪证券 · 09-04
甘李药业：高管减持潮背后，财务与转型双重考验显现
甘李药业：9月2日高级管理人员李智减持股份合计1000股
证券之星 · 09-03
甘李药业：9月2日高级管理人员李智减持股份合计1000股
甘李药业：潜在交易总价值高达7.26亿欧元（不含特许权使用费）
美股速递 · 09-03
甘李药业：潜在交易总价值高达7.26亿欧元（不含特许权使用费）
甘李药业(603087.SH)获得GZC8072片新适应症《药物临床试验批准通知书》
智通财经 · 09-03
甘李药业(603087.SH)获得GZC8072片新适应症《药物临床试验批准通知书》
甘李药业：子公司获GZC8072片新适应症临床试验批准
格隆汇 · 09-03
甘李药业：子公司获GZC8072片新适应症临床试验批准
甘李药业：9月1日都凯、李智减持股份合计2.05万股
证券之星 · 09-02
甘李药业：9月1日都凯、李智减持股份合计2.05万股
长城国瑞证券：给予甘李药业买入评级
证券之星 · 08-31
长城国瑞证券：给予甘李药业买入评级
股市必读：甘李药业新发布《关于公司持股5%以上股东部分股份解押的公告》
证券之星 · 08-28
股市必读：甘李药业新发布《关于公司持股5%以上股东部分股份解押的公告》
甘李药业(603087)6月30日股东户数7.56万户，较上期减少7.78%
证券之星 · 08-26
甘李药业(603087)6月30日股东户数7.56万户，较上期减少7.78%
图解甘李药业中报：第二季度单季净利润同比增长43.03%
证券之星 · 08-26
图解甘李药业中报：第二季度单季净利润同比增长43.03%
8月25日甘李药业涨5.06%，招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 08-25
8月25日甘李药业涨5.06%，招商国证生物医药指数(LOF)C基金重仓该股
甘李药业（603087）25.93万股限售股将于8月24日解禁，占总股本0.04%
证券之星 · 08-24
甘李药业（603087）25.93万股限售股将于8月24日解禁，占总股本0.04%
每周股票复盘：甘李药业（603087）0.0434%限售股8月24日上市
证券之星 · 08-23
每周股票复盘：甘李药业（603087）0.0434%限售股8月24日上市
甘李药业：公司日常经营状态良好
证券之星 · 08-21
甘李药业：公司日常经营状态良好
甘李药业：高管减持系个人资金需求
证券之星 · 08-21
甘李药业：高管减持系个人资金需求
加载更多
公司概况
公司名称：
甘李药业股份有限公司
所属行业：
医药制造业
上市日期：
2020-06-29
主营业务：
甘李药业股份有限公司的主营业务是胰岛素类似物原料药及注射剂研发、生产和销售。公司的主要产品是甘精胰岛素注射液、赖脯胰岛素注射液、精蛋白锌重组赖脯胰岛素混合注射液、门冬胰岛素注射液、门冬胰岛素30注射液、精蛋白人胰岛素混合注射液。
发行价格：
63.32
{"stockData":{"symbol":"603087","market":"SH","secType":"STK","nameCN":"甘李药业","latestPrice":69.2,"timestamp":1789369201000,"preClose":66.34,"halted":0,"volume":6356509,"delay":0,"changeRate":0.0431,"floatShares":561000000,"shares":597000000,"eps":1.9244,"marketStatus":"已收盘","change":2.86,"latestTime":"09-14 15:00:00","open":65.95,"high":69.5,"low":65.91,"amount":433000000,"amplitude":0.0541,"askPrice":69.2,"askSize":1,"bidPrice":69.19,"bidSize":97,"shortable":0,"etf":0,"ttmEps":1.9244,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789435800000},"marketStatusCode":5,"adr":0,"adjPreClose":66.34,"symbolType":"stock","openAndCloseTimeList":[[1789349400000,1789356600000],[1789362000000,1789369200000]],"highLimit":72.97,"lowLimit":59.71,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":597432169,"isCdr":false,"pbRate":3.53,"roa":"--","peRate":35.95926,"roe":"5.15%","epsLYR":1.93,"committee":0.655814,"marketValue":41342000000,"turnoverRate":0.0113,"status":0,"floatMarketCap":38850000000},"requestUrl":"/m/hq/s/603087","defaultTab":"news","newsList":[{"id":"2667073085","title":"每周股票复盘：甘李药业（603087）GZC8072片完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2667073085","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667073085?lang=zh_cn&edition=full","pubTime":"2026-09-13 01:48","pubTimestamp":1789235295,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，甘李药业报收于66.34元，较上周的70.1元下跌5.36%。公司公告汇总关于GZC8072片Ⅰ期临床试验完成首例受试者给药的公告甘李药业股份有限公司全资子公司甘李药业山东有限公司自主研发的GZC8072片，于近日在中国成功完成Ⅰ期临床试验首例受试者给药。关于完成工商登记信息变更的公告甘李药业股份有限公司已完成工商登记信息变更，公司总股本和注册资本因2026年限制性股票激励计划630,000股授予登记完成而相应增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149513139","title":"甘李药业Gzc8072首个人体I期临床研究完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1149513139","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149513139?lang=zh_cn&edition=full","pubTime":"2026-09-09 21:01","pubTimestamp":1788958893,"startTime":"0","endTime":"0","summary":"甘李药业宣布，其自主研发的新型超长效口服多肽GLP-1受体激动剂Gzc8072，已在首次人体I期临床研究中完成首例受试者给药。Gzc8072凭借其创新的分子设计，旨在实现每周一次的口服给药方案，从而大幅提升患者用药的便利性与依从性。随着首例受试者的顺利入组，该研究的后续数据读出备受期待，其结果将为Gzc8072的后续临床开发策略提供关键依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665632905","title":"甘李药业（603087）披露GZC8072片Ⅰ期临床试验完成首例受试者给药公告，9月8日股价上涨0.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665632905","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665632905?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:57","pubTimestamp":1788861451,"startTime":"0","endTime":"0","summary":"截至2026年9月8日收盘，甘李药业报收于69.39元，较前一交易日上涨0.39%，最新总市值为414.56亿元。该股当日开盘69.2元，最高69.9元，最低68.57元，成交额达3.12亿元，换手率为0.8%。甘李药业股份有限公司全资子公司甘李药业山东有限公司自主研发的GZC8072片，于近日在中国成功完成Ⅰ期临床试验首例受试者给药。该产品已获国家药监局多项临床试验批准，截至2026年6月30日，累计研发投入6,633.26万元。目前全球尚无GLP-1口服周制剂获批上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800028190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665397088","title":"甘李药业(603087.SH)：GZC8072片Ⅰ期临床试验完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2665397088","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665397088?lang=zh_cn&edition=full","pubTime":"2026-09-07 15:52","pubTimestamp":1788767548,"startTime":"0","endTime":"0","summary":"智通财经APP讯，甘李药业 发布公告，公司全资子公司甘李药业山东有限公司自主研发的GZC8072片正在中国开展Ⅰ期临床试验，于近日成功完成首例受试者给药。GZC8072片是新一代偏向型超长效多肽口服周制剂，正在开展用于肥胖或超重、2型糖尿病的适应症的临床试验。据悉，该产品于2026年8月、9月分别获得国家药品监督管理局下发的适应症为肥胖或超重、2型糖尿病的《药品临床试验批准通知书》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492741.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","BK0239","MDTX","603087","PSYK","IBBJ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664331601","title":"甘李药业：9月3日董事李智、宋维强减持股份合计1.3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664331601","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664331601?lang=zh_cn&edition=full","pubTime":"2026-09-04 20:01","pubTimestamp":1788523302,"startTime":"0","endTime":"0","summary":"证券之星消息，根据9月4日市场公开信息、上市公司公告及交易所披露数据整理，甘李药业最新董监高及相关人员股份变动情况：2026年9月3日公司董事李智、董事,高级管理人员宋维强共减持公司股份1.3万股，占公司总股本为0.0022%。甘李药业近半年内的董监高及核心技术人员增减持详情如下：甘李药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出2589.94万，融资余额减少；融券净流入4700.0，融券余额增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400037763.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664996382","title":"甘李药业：高管减持潮背后，财务与转型双重考验显现","url":"https://stock-news.laohu8.com/highlight/detail?id=2664996382","media":"新浪证券","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664996382?lang=zh_cn&edition=full","pubTime":"2026-09-04 15:25","pubTimestamp":1788506700,"startTime":"0","endTime":"0","summary":"胰岛素集采重塑行业格局之后，甘李药业完成管理层迭代，押注 GLP\u001e1 管线，接连签下大额海外授权订单，市场对其转型预期升温。整体来看，甘李药业站在行业转型十字路口，手握大额 BD 利好，但财务质量、高管减持、管线兑现、主业增长多重风险交织。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-09-04/doc-iniqryew1339260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664871740","title":"甘李药业：9月2日高级管理人员李智减持股份合计1000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664871740","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664871740?lang=zh_cn&edition=full","pubTime":"2026-09-03 20:01","pubTimestamp":1788436893,"startTime":"0","endTime":"0","summary":"证券之星消息，根据9月3日市场公开信息、上市公司公告及交易所披露数据整理，甘李药业最新董监高及相关人员股份变动情况：2026年9月2日公司高级管理人员李智共减持公司股份1000.0股，占公司总股本为0.0002%。甘李药业近半年内的董监高及核心技术人员增减持详情如下：甘李药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出1790.63万，融资余额减少；融券净流入1000.0，融券余额增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300038197.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184990997","title":"甘李药业：潜在交易总价值高达7.26亿欧元（不含特许权使用费）","url":"https://stock-news.laohu8.com/highlight/detail?id=1184990997","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184990997?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:53","pubTimestamp":1788429200,"startTime":"0","endTime":"0","summary":"甘李药业宣布，其潜在交易总价值最高可达7.26亿欧元。值得注意的是，这一数字尚未将特许权使用费纳入考量范围。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664270568","title":"甘李药业(603087.SH)获得GZC8072片新适应症《药物临床试验批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664270568","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664270568?lang=zh_cn&edition=full","pubTime":"2026-09-03 16:31","pubTimestamp":1788424286,"startTime":"0","endTime":"0","summary":"智通财经APP讯，甘李药业(603087.SH)发布公告，公司全资子公司甘李药业山东有限公司于近日收到国家药品监督管理局下发的关于在研药品GZC8072片的《药物临床试验批准通知书》，同意本品开展2型糖尿病适应症的临床试验。GZC8072片是甘李药业自主研发的新一代偏向型超长效多肽口服周制剂。该分子依托公司NovaPeptide多肽技术平台与SupOraTide口服多肽技术平台，在提升分子活性、延长半衰期的基础上，同时显著改善口服生物利用度，从而有望支持每周一次口服给药的方案。截至公告披露日，全球范围内尚无用于2型糖尿病的GLP-1口服周制剂片剂获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MDTX","PSYK","BK0239","BMED","IBBJ","603087","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664820899","title":"甘李药业：子公司获GZC8072片新适应症临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664820899","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664820899?lang=zh_cn&edition=full","pubTime":"2026-09-03 16:29","pubTimestamp":1788424185,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664819075","title":"甘李药业：9月1日都凯、李智减持股份合计2.05万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819075","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664819075?lang=zh_cn&edition=full","pubTime":"2026-09-02 20:01","pubTimestamp":1788350489,"startTime":"0","endTime":"0","summary":"证券之星消息，根据9月2日市场公开信息、上市公司公告及交易所披露数据整理，甘李药业最新董监高及相关人员股份变动情况：2026年9月1日公司董事,高级管理人员都凯、高级管理人员李智共减持公司股份2.05万股，占公司总股本为0.0034%。甘李药业近半年内的董监高及核心技术人员增减持详情如下：甘李药业的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出5596.39万，融资余额减少；融券净流出1.9万，融券余额减少。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200038497.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663074159","title":"长城国瑞证券：给予甘李药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2663074159","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663074159?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:19","pubTimestamp":1788171554,"startTime":"0","endTime":"0","summary":"长城国瑞证券有限公司胡晨曦近期对甘李药业进行研究并发布了研究报告《海外业务高速增长，创新产品NDA在即》，给予甘李药业买入评级。考虑公司胰岛素集采后销量持续放量，叠加海外业务高速增长、博凡格鲁肽注射液、胰岛素周制剂GZR4等在研管线推进顺利，成长动能较强，我们维持其“买入”评级。本文数据来源于长城国瑞证券有限公司，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100026508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662823087","title":"股市必读：甘李药业新发布《关于公司持股5%以上股东部分股份解押的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662823087","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662823087?lang=zh_cn&edition=full","pubTime":"2026-08-28 02:06","pubTimestamp":1787854011,"startTime":"0","endTime":"0","summary":"截至2026年8月27日收盘，甘李药业报收于71.38元，上涨0.11%，换手率1.69%，成交量9.48万手，成交额6.75亿元。当日关注点交易信息汇总：8月27日主力资金净流出2738.19万元，占总成交额4.06%。公司公告汇总：持股5%以上股东旭特宏达于8月25日解除质押880,000股，解押后其累计质押股份占公司总股本1.43%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800005710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662945687","title":"甘李药业(603087)6月30日股东户数7.56万户，较上期减少7.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662945687","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662945687?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:32","pubTimestamp":1787736779,"startTime":"0","endTime":"0","summary":"证券之星消息，近日甘李药业披露，截至2026年6月30日公司股东户数为7.56万户，较3月31日减少6378.0户，减幅为7.78%。在生物制品行业个股中，甘李药业股东户数高于行业平均水平，截至6月30日，生物制品行业平均股东户数为3.53万户。从股价来看，2026年3月31日至2026年6月30日，甘李药业区间跌幅为9.61%，在此期间股东户数减少6378.0户，减幅为7.78%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600039212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662061759","title":"图解甘李药业中报：第二季度单季净利润同比增长43.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662061759","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662061759?lang=zh_cn&edition=full","pubTime":"2026-08-26 02:03","pubTimestamp":1787680993,"startTime":"0","endTime":"0","summary":"证券之星消息，甘李药业2026年中报显示，上半年度公司主营收入22.23亿元，同比上升7.56%；归母净利润6.1亿元，同比上升1.01%；扣非净利润5.8亿元，同比上升18.91%；其中2026年第二季度，公司单季度主营收入13.45亿元，同比上升24.31%；单季度归母净利润4.17亿元，同比上升43.03%；单季度扣非净利润3.94亿元，同比上升44.23%；负债率8.25%，投资收益2912.3万元，财务费用-1852.14万元，毛利率74.13%。财报数据概要请见下图:本文数据来源于甘李药业2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600004477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662078216","title":"8月25日甘李药业涨5.06%，招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662078216","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662078216?lang=zh_cn&edition=full","pubTime":"2026-08-25 16:32","pubTimestamp":1787646740,"startTime":"0","endTime":"0","summary":"证券之星消息，8月25日甘李药业涨5.06%，收盘报68.78元，换手率2.3%，成交量12.91万手，成交额8.68亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共30家，其中持有数量最多的公募基金为招商基金的招商国证生物医药指数C。招商国证生物医药指数C目前规模为15.39亿元，最新净值0.4003，较上一交易日下跌4.98%，近一年下跌9.9%。招商国证生物医药指数C的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500033629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["399441","161726","603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661241352","title":"甘李药业（603087）25.93万股限售股将于8月24日解禁，占总股本0.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661241352","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661241352?lang=zh_cn&edition=full","pubTime":"2026-08-24 08:02","pubTimestamp":1787529755,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，甘李药业于8月24日将有25.93万股限售股份解禁，为公司首发原股东限售股份，占公司总股本0.04%。最近一年内，该股累计解禁329.87万股，占总股本的0.55%。本次解禁后，公司还有3601.56万股限售股份，占总股本6.03%。甘李药业主营业务：胰岛素类似物原料药及注射剂研发、生产和销售。本文数据来源于甘李药业公告，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400002546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661211540","title":"每周股票复盘：甘李药业（603087）0.0434%限售股8月24日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2661211540","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661211540?lang=zh_cn&edition=full","pubTime":"2026-08-23 01:22","pubTimestamp":1787419332,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，甘李药业报收于68.43元，较上周的74.98元下跌8.74%。相关股份因甘忠如出具解除延长锁定的书面通知，将于2026年8月24日上市流通。首次公开发行部分限售股上市流通公告甘李药业发布首次公开发行部分限售股上市流通公告，本次上市流通数量为259,327股，占公司总股本的0.0434%，涉及股东为南京铸成顺康创业投资合伙企业。公司总股本为597,432,169股，本次变动后有限售条件流通股减少至36,015,582股，无限售条件流通股相应增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000127.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661265853","title":"甘李药业：公司日常经营状态良好","url":"https://stock-news.laohu8.com/highlight/detail?id=2661265853","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661265853?lang=zh_cn&edition=full","pubTime":"2026-08-21 16:33","pubTimestamp":1787301207,"startTime":"0","endTime":"0","summary":"证券之星消息，甘李药业(603087)08月21日在投资者关系平台上答复投资者关心的问题。投资者提问：今天的大幅下跌说明了什么？甘李药业回复：尊敬的投资者您好，公司日常经营状态良好，严格按照法律法规履行信息披露义务，不存在应披露而未披露的重大事项。股价波动受宏观经济、行业周期及市场情绪等多重因素影响，短期走势并不能充分反映公司的长期价值。公司将继续聚焦主业，以扎实的经营业绩回馈广大投资者。感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100029146.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661265889","title":"甘李药业：高管减持系个人资金需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2661265889","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661265889?lang=zh_cn&edition=full","pubTime":"2026-08-21 16:33","pubTimestamp":1787301206,"startTime":"0","endTime":"0","summary":"证券之星消息，甘李药业08月21日在投资者关系平台上答复投资者关心的问题。公司已于8月7日披露了《董事、高级管理人员减持股份计划公告》，根据公告，该次减持系高管个人资金需求，拟减持股份来源于公司股权激励计划，减持比例合计不超过公司总股本的0.14%，规模较小，不会对公司治理结构及持续经营产生影响。股价波动受宏观经济、行业周期、市场情绪等多种因素影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100029143.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603087","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789411857673,"stockEarnings":[{"period":"1week","weight":0.0012},{"period":"1month","weight":-0.0771},{"period":"3month","weight":0.2621},{"period":"6month","weight":0.1222},{"period":"1year","weight":-0.0488},{"period":"ytd","weight":0.0361}],"compareEarnings":[{"period":"1week","weight":-0.012},{"period":"1month","weight":-0.0107},{"period":"3month","weight":-0.0505},{"period":"6month","weight":-0.0437},{"period":"1year","weight":0.0038},{"period":"ytd","weight":-0.021}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"甘李药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"75587人(较上一季度减少7.78%)","perCapita":"7427股","listingDate":"2020-06-29","address":"北京市通州区漷县镇南凤西一路8号","registeredCapital":"59743万元","survey":" 甘李药业股份有限公司的主营业务是胰岛素类似物原料药及注射剂研发、生产和销售。公司的主要产品是甘精胰岛素注射液、赖脯胰岛素注射液、精蛋白锌重组赖脯胰岛素混合注射液、门冬胰岛素注射液、门冬胰岛素30注射液、精蛋白人胰岛素混合注射液。","listedPrice":63.32},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"甘李药业(603087)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供甘李药业(603087)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"甘李药业,603087,甘李药业股票,甘李药业股票老虎,甘李药业股票老虎国际,甘李药业行情,甘李药业股票行情,甘李药业股价,甘李药业股市,甘李药业股票价格,甘李药业股票交易,甘李药业股票购买,甘李药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"甘李药业(603087)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供甘李药业(603087)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}